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Abstract
Background: Longer patient intervals can lead to more late-stage cancer diagnoses and higher mortality rates. Individuals may
delay presenting to primary care with red flag symptoms and instead turn to the internet to seek information, purchase
over-the-counter medication, and change their diet or exercise habits. With advancements in machine learning, there is the potential
to explore this complex relationship between a patient’s symptom appraisal and their first consultation at primary care through
linkage of existing datasets (eg, health, commercial, and online).
Objective: Here, we aimed to explore feasibility and acceptability of symptom appraisal using commercial- and health-data
linkages for cancer symptom surveillance.
Methods: A proof-of-concept study was developed to assess the general public’s acceptability of commercial- and health-data
linkages for cancer symptom surveillance using a qualitative focus group study. We also investigated self-care behaviors of
ovarian cancer patients using high-street retailer data, pre- and postdiagnosis.
Results: Using a high-street retailer’s data, 1118 purchases—from April 2013 to July 2017—by 11 ovarian cancer patients and
one healthy individual were analyzed. There was a unique presence of purchases for pain and indigestion medication prior to
cancer diagnosis, which could signal disease in a larger sample. Qualitative findings suggest that the public are willing to consent
to commercial- and health-data linkages as long as their data are safeguarded and users of this data are transparent about their
purposes.
Conclusions: Cancer symptom surveillance using commercial data is feasible and was found to be acceptable. To test efficacy
of cancer surveillance using commercial data, larger studies are needed with links to individual electronic health records.
(JMIR Cancer 2018;5(1):e10447)   doi:10.2196/10447
KEYWORDS
cancer; early diagnosis; proof of concept; focus group; acceptability; data linkage; cancer surveillance
JMIR Cancer 2018 | vol. 5 | iss. 1 | e10447 | p.1https://cancer.jmir.org/2019/1/e10447/
(page number not for citation purposes)
Flanagan et alJMIR CANCER
XSL•FO
RenderX
Introduction
Early diagnosis is key to increasing the chances of 10-year
survival rates and the number of people living beyond cancer.
However, when the symptoms first present, only a very small
proportion of people believe that their symptoms might be a
sign of cancer; failure to recognize the signs and symptoms of
cancer have been strongly linked to delays in help-seeking [1,2].
While greater symptom awareness and body vigilance are a key
part of the patient appraisal and help-seeking [3], it has been
suggested that people might use past experiences to reassure
themselves that their symptoms are normal [4]. Ovarian cancer
symptoms (eg, feeling bloated and abdominal pain) [5,6] and
women’s personal experiences are prime examples of how
symptoms can be normalized and potentially lead to delays in
diagnosis [7].
Epithelial ovarian cancer has no specific recognizable symptoms
and, as a result, most women are diagnosed at a late stage when
the cancer has already spread around the peritoneum and the
prognosis is poor. Approximately 7400 new cases of ovarian
cancer are diagnosed each year in the United Kingdom, with
over 4000 women dying from the disease each year [8]. The
10-year survival rate is only 35% in the United Kingdom; the
survival rate is dramatically different if patients are diagnosed
earlier with stage 1 disease (90%) compared with stage 3 or 4
(5%-15%), which unfortunately includes the majority of patients.
Given that screening with cancer antigen 125 (CA 125) and
transvaginal ultrasound do not appear to reduce mortality
associated with ovarian cancer [9,10], the key to reducing this
mortality is earlier diagnosis among women who are
symptomatic, identifying those at high risk, and prevention.
Women with ovarian cancer usually report to primary care with
symptoms at least six months before diagnosis; this suggests
that symptom presentation and management are key parts of
understanding ovarian cancer prognosis better [11]. A previous
study showed a third of patients with ovarian cancer receive
prescription medication to manage irritable bowel disease,
constipation, stress, and depression before being diagnosed with
cancer [12]. Qualitative studies on patients’ symptoms appraisal
support the fact that women with ovarian cancer self-medicate
their symptoms before they become debilitating [7]. If ovarian
cancer symptoms overlap with patients’ sense of self and
normality before they are perceived as signs of pathology [13],
persistent use of over-the-counter medication could be an
indication of ovarian cancer.
Most self-care evidence prior to diagnosis comes from
retrospective studies with cancer patients, by the use of
self-reported data from surveys and qualitative interviews [14].
Although they are important in understanding what may have
caused delays in help-seeking, they have limited applications
in real-life interventions. On the contrary, big data refers to
massive amounts of data collected at rapid and efficient rates
due to technological advances [15]. Big data in health care has
the major potential to connect information from different sources
to generate real-time datasets and outputs to monitor illnesses
[16,17]. For instance, recent studies have utilized digital data
to gain a better understanding of online
health-information-searching by conducting large-scale analyses
of search engine logs. By analyzing the sequence of terms
inputted about health, studies have demonstrated the ability to
detect influenza [18] and dengue [19] outbreaks, to discover
side effects of medications [20], to assess effectiveness of
internet-based preventative health programs [21], and to predict
the changing information needs of women with breast cancer,
from diagnosis to treatment [22].
Furthermore, a recent study has shown the feasibility of using
online search terms describing cancer-relevant symptoms to
predict forthcoming diagnoses of early-stage pancreatic cancer
[23]. In addition to the use of online search engine logs to
forecast early signs of cancer, future studies could use other
sources of commercial data (ie, loyalty card and tracker data,
as well as social media data collected by commercial
organizations to understand consumer behaviors) to further
understand how people evaluate and implement self-care for
their cancer symptoms. However, one of the key challenges of
using personal, commercial big data in cancer research is not
knowing whether using commercial data to predict cancer is an
acceptable approach within this decade, and whether it will
provide meaningful insights into symptom appraisal and
help-seeking.
Here, we aimed to evaluate inquiries on both acceptability and
feasibility of cancer symptom surveillance using commercial
data with a proof-of-concept study. Proof-of-concept studies
are used to establish whether the proposed methodology or the
concept is valid and feasible [24]. We used ovarian cancer as
our primary cancer for our case study. We investigated the
proof-of-concept evidence within the purchasing behaviors of
women pre- and postdiagnosis using data from a high-street
retailer that contains purchases of pain and indigestion
medications. Furthermore, to better understand public attitudes
and whether this project can be carried out with prospective
real-time data, we assessed the acceptability of commercial-
and health-data linkage for cancer symptom surveillance among
a healthy population.
Methods
Ovarian Cancer Case Study
Study Design and Setting
We conducted a retrospective study of purchasing behaviors
using ovarian cancer patients’ pre- and postdiagnosis data held
in connection with a high-street retailer loyalty card. The study
was facilitated by the Economic and Social Research Council
(ESRC)-funded Consumer Data Research Centre (CDRC),
which is based at University College London (UCL), London,
United Kingdom. The CDRC has a license agreement with the
high-street retailer, which agreed to support the study. Under
CDRC guidelines, the data we requested were considered
controlled data, which are defined as “data which need to be
held under the most secure conditions with stringent access
restrictions.” This meant that all data analysis was performed
at a secure data laboratory based at UCL. JMF and YH were
the only people with access to the data.
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Data Collection
With the support from a patient representative group from a
charity, Ovarian Cancer Action, 70 patients who were not under
treatment for ovarian cancer from January to May 2017 received
an invitation pack, including a study information sheet, a
self-report survey, a consent form, and a free-post envelope.
Once consent forms and surveys were returned, the researcher
provided the high-street retailer with the unique loyalty card ID
and a unique study ID for each of the consenting participants.
The high-street retailer extracted data to be transferred into the
CDRC secure lab using an encrypted server. The researchers
used the unique study IDs to merge the survey data with the
retailer data. The individuals’ data collected through the survey
were not accessible to the retailer and the CDRC. Due to time
restrictions, we included one healthy subject in the study.
Self-Report Survey
A self-report survey was designed to obtain information about
the timeline of the cancer diagnosis, symptoms observed,
demographics, and the loyalty card usage (see Multimedia
Appendix 1). We asked the participants to report the first time
they recognized signs and symptoms, the first time they booked
an appointment with a health care professional, and the month
and year of diagnosis. The symptoms included irregular periods
or vaginal bleeding after menopause, back pain, lower-tummy
pain, passing urine more than usual, constipation, pain during
sex, weight loss, persistent bloating, loss of appetite, and feeling
tired. Patients were given other as a response option. In addition,
the survey recorded self-reported purchases of over-the-counter
medication.
Data Analysis
Feasibility outcomes and participant characteristics were
demonstrated using descriptive statistics. Due to variance in the
frequency of purchases, we calculated the proportion of
individual purchases matching the categories of interest—hair
care products as one category and pain plus indigestion
medication as the other category. For each category, the monthly
ratio of each individual purchase to the overall purchases was
computed. For example, the proportion of pain plus indigestion
medication was calculated as (pain medication + indigestion
medication)/all purchases in the month. The overall proportions,
as reported in Figure 1, were calculated as averages for the
calendar months across the study period. In Figure 2, patients
were aligned with their diagnosis dates; an average proportion
was calculated across the patients for each month prior to
diagnosis (6/11, 55%) and postdiagnosis (11/11, 100%). Month
and year of diagnosis were recorded for each ovarian cancer
patient using the self-report survey and all purchase dates were
aligned with pre- or postdiagnostic times. Where an ovarian
cancer patient diagnosis was prior to the earliest purchase data,
all data points were recorded as postdiagnosis from the date of
the earliest purchase. The confidence interval of the mean was
calculated using the R package Publish and ci.mean function.
The data were analyzed using R version 3.2.3 (The R
Foundation).
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Figure 1. Overall purchase proportions. For each month between April 2013 and July 2017, the total purchases for each category were summed and
divided by the number of all purchases in that month for the ovarian cancer patients (blue line), compared with the average monthly purchase proportion
for that category for the healthy control subject (red dotted line). A. Purchases of pain and indigestion medication. B. Purchases of hair care products.
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Figure 2. Pain and indigestion medication purchases stratified into pre- and postdiagnosis. Average monthly purchase proportions for ovarian cancer
patients (blue line) were compared with those of the healthy control subject (red dotted line). A. Purchases for the pain and indigestion medication
category during the prediagnostic period. B. Purchases for the pain and indigestion medication category during the postdiagnostic period.
Focus Group Study
Study Design and Setting
Between January and April 2017, we conducted four focus
groups with members of the general public, 25-74 years of age,
aiming to explore their acceptability of, and their attitudes
toward, using commercial-data linkage for the purpose of cancer
symptom surveillance. Participants from all parts of the United
Kingdom were invited to attend a focus group based at the
researchers’ offices at UCL in London, United Kingdom.
Research participants were recruited by placing an online
recruitment advertisement on Twitter and Facebook, as well as
by asking friends and colleagues of the researchers to share an
email invitation. The online recruitment advertisement and email
invitation promoted the fact that travel expenses would be
reimbursed and focus groups would take place during
lunchtime—with free refreshments included—so that
participants could enjoy an afternoon in London afterward.
Those interested in participating were instructed to click on a
link to an online survey that asked individuals for their contact
details and age. Individuals were selected for the study through
the use of purposive sampling, which ensured that each focus
group included individuals of different ages. Purposive sampling
was used in this study, as previous research has shown a
difference by age in the acceptability of sharing personal data,
with younger individuals being more accepting of providing
their personal information to commercial companies [25].
Each focus group was conducted for approximately one hour,
facilitated by two members of the research team; all focus groups
were led by one researcher, with another researcher assisting
with facilitating the sessions. The role of the lead facilitator was
to lead the discussion by asking the questions in the topic guide,
encouraging all members to participate, and qualitatively
balancing the amount of content that came from any one
participant. The role of the assistant facilitator was to write field
notes and to keep track of the timing.
At the beginning of each focus group session, participants were
asked to complete a paper survey measuring demographic
characteristics—age, gender, ethnicity, employment, and
education—and use of the following: loyalty cards, online search
engines, online shopping sites, health trackers, and social media
(eg, Facebook, Twitter, and Instagram). The survey took no
longer than five minutes to complete. The survey items have
not been validated, but were included to allow us to describe
the sample and to identify whether there were any biases in the
groups (ie, if any group was overrepresented by participants of
a particular demographic or by those who were more likely to
use the apps or online services of interest).
Focus group questions were developed by the research team
and reviewed for content and reliability. Two patient
representatives from Cancer Research UK also reviewed the
acceptability and the readability of the topic guide and provided
further guidance. During the focus groups, the concept of data
linkage was first introduced by asking participants how they
felt about sharing their personal information with commercial
companies and what they thought their data were used for. The
discussion then moved on to asking participants about their
attitudes toward researchers linking their commercial data with
their health records to understand how their behaviors and that
of others are linked to health conditions. The end of the
discussion then focused more specifically on understanding
participants’ thoughts on the potential to use commercial- and
health-data linkage to predict cancer in the future using machine
learning. The lead facilitator provided a description of this
feasibility study in order for participants to understand the
context for this discussion and the types of commercial data
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that may be used for the purpose of cancer surveillance in the
future (eg, Fitbit and loyalty card data; see Multimedia Appendix
2).
Data Analysis
The focus groups were audiotaped and the audio files were
transcribed verbatim. The researchers validated the accuracy of
transcripts by comparing them with the audio files and the
facilitators’ notes. The transcripts were analyzed using thematic
analysis [26] using NVivo 11 software (QSR International).
Interview transcripts were read repeatedly to extract themes,
which were formatted into matrices to allow comparison of
themes across participants and to identify the salient and
prevalent dimensions of attitudes.
Ethics Approval and Consent to Participate
Both studies have been reviewed by the University College
London Research Ethics Committee and received favorable
opinions (case study reference No. 6769/004 and focus group
study reference No. 4657/002). The case study was also
submitted to be reviewed by the CDRC Research Approvals
Group (reference No. CDRC 018), which assessed the feasibility
of the study and facilitated engagement with the high-street
retailer. YH, JMF, and XS received the Safe User of Research
Data Environments (SURE) training from the UK Data Service
and had been subject to criminal records checks to receive
permission to have access to data at the secure laboratories.
Consent for Publication
We received individual consent from focus group participants
to use their anonymized data in research publications, reports,
webpages, and other research outputs. All anonymized outputs
from the ovarian cancer case study were approved in accordance
with CDRC data dissemination policies. Individual consent
forms are being kept in a secure locker at YH’s department
based at UCL for 10 years, in line with UCL’s data retention
regulations.
Results
Ovarian Cancer Case Study
Feasibility Outcomes
Of the 70 patients who received the invitation, 18 women (26%)
consented to take part in the study (see Table 1). Two people
contacted the research team and reported not having a loyalty
card as their reason for not participating. Of the 18 women who
returned their consent, the median age was 55 (35-69) years and
17 women (94%) were white British. Of the 18 subjects, 7 (39%)
had an unverified name or loyalty card number. We found that
17 out of the 18 (94%) participants recalled at least one symptom
before their first visit to primary care; pain and fatigue were the
most recognized symptoms. In total, purchase data from 11
ovarian cancer patients and one control subject were included
in the final database. The high-street retailers retain individual
purchase data for three years before aggregating the past
purchase data. As a result, data from 1118 individual purchases
were obtained from the retailer data ranging from April 2013
to July 2017. Of the final sample, 5 out of 11 patients (45%)
were diagnosed before April 2013; therefore, all of their data
were treated as postdiagnosis.
Proof-of-Concept Outcomes
Due to the higher patient recall of pain as one of the recognized
symptoms before diagnosis, pain medication inclusive of
indigestion and gastrointestinal tablets was chosen as the primary
medication to monitor retrospectively. We selected hair care
products as the control purchase category, which was expected
to be unrelated to ovarian cancer symptoms. During the analysis
period, there were 88 individual purchases of pain or indigestion
medication. The monthly proportion of purchases of pain and
indigestion medication in ovarian cancer patients ranged from
0% to 30% (8/27) across each of the months, in comparison to
that of the healthy control subject, which accounted for
approximately 1% (1/72) of all of their purchases (see Figure
1A). In comparison, there were 74 individual purchases of hair
care products among the purchases. Hair care products
accounted for approximately 18% (13/72) of all purchases by
the healthy control compared with 0% to 38% (9/24) each month
for the ovarian cancer patients (see Figure 1B).
To test for self-care behaviors before diagnosis, we split the
timeline and demonstrated the purchasing trends by calculating
the purchases for each month pre- and postdiagnosis. Figure 2
shows that around 12 months before diagnosis, women started
purchasing pain and indigestion medication, while their behavior
is the same as the healthy control individual before their
potential nonapparent symptoms might have started to present
themselves. We found pain and indigestion medication
representing 12 out of 202 (5.9%, 95% CI 1.0-8.8) purchases
prediagnosis and 73 out 1011 (7.22%, 95% CI 4.5-15.0)
purchases postdiagnosis, compared with the healthy control at
1 out of 72 (1%) purchases (see Figure 2). In comparison, the
hair care products represented 24 out of 202 (11.9%, 95% CI
5.3-26.7) purchases before diagnosis and 37 out of 1011 (3.66%,
95% CI 2.3-6.6) purchases postdiagnosis in the ovarian cancer
patients, compared with 13 out of 72 (18%) purchases in the
healthy control.
Focus Group Studies
Acceptability of Commercial- and Health-Data Linkage
for Cancer Symptom Surveillance
In total, 27 people took part in one of four focus groups (see
Table 2). Overall, 19 out of the 27 participants (70%) were
female with at least one to three male participants in each group.
Distribution of participant characteristics is presented in Table
2. Four key themes were identified from the discussions in all
the focus groups: conditional acceptance of commercial- and
health-data linkage and symptom surveillance, beliefs about
accuracy of the data, perceived benefits, and considerations for
communication strategies.
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Table 1. Ovarian cancer case study participant characteristics.
Ovarian cancer patients (N=11)All respondents (N=18) Participant characteristics
56 (35-69)55 (35-69)Age in years, median (range)
Ovarian cancer diagnosis, n (%)
11 (100)17 (94)Yes
0 (0)1 (6)No
Ethnicity, n (%)
10 (91)17 (94)White
1 (9)1 (6)Missing
Symptoms observed before diagnosis (all respondents, N=17), n (%)
9 (82)15 (88)Any
1 (9)1 (6)Irregular periods
6 (55)12 (71)Pain (back, tummy, urinary, during sex)
1 (9)1 (6)Constipation
1 (9)1 (6)Weight loss
1 (9)3 (18)Bloating
2 (18)4 (24)Loss of appetite
6 (55)7 (41)Fatigue
Perceived health, n (%)
3 (27)4 (22)Excellent to very good
5 (45)10 (56)Good to fair
4 (36)4 (22)Poor
Loyalty card use, n (%)
8 (72)13 (72)All the time/often
2 (18)4 (22)Sometimes/not very often
1 (9)1 (6)Not at all
Subscription to loyalty cards provided by high-street retailers, n (%)
10 (91)17 (94)Tesco
11 (100)15 (83)Boots
8 (73)13 (72)Sainsbury
7 (64)10 (56)All three above
4 (36)8 (44)Coop
1 (9)1 (6)Morrison
3 (27)4 (22)Superdrug
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Table 2. Focus group study participant characteristics.
Participants (N=27), n (%)Participant characteristics
Focus group distribution
5 (19)Group 1
6 (22)Group 2
7 (26)Group 3
9 (33)Group 4
55 (25-71)Age in years, median (range)
Gender 
8 (27)Male
19 (70)Female
Ethnicity
25 (93)White British
1 (4)Other white
1 (4)Other mixed
Employment
13 (48)Full-time employee
3 (11)Part-time employee
7 (26)Retired
2 (7)Student
1 (4)Disabled or too ill to work
1 (4)Full-time homemaker
Education
6 (22)GCSEa/O Levelb/CSEc, vocation qualifications, or A Leveld
18 (67)Higher education (degree or higher)
3 (11)No formal qualifications
Number of loyalty cards
10 (37)None
2 (7)One card
11 (41)Between two and five cards
4 (15)More than five cards
Use of Facebook
17 (63)Yes
10 (37)No
Use of Instagram
7 (26)Yes
20 (74)No
Use of online search engines
25 (93)Yes
2 (7)No
Use of online shopping
19 (70)Yes
8 (30)No
Use of health trackers
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Participants (N=27), n (%)Participant characteristics
10 (37)Yes
17 (63)No
Use of Twitter
10 (37)Yes
17 (63)No
aGCSE: General Certificate of Secondary Education.
bO Level: Ordinary Level.
cCSE: Certificate of Secondary Education.
dA Level: Advanced Level.
Conditional Acceptance of Commercial- and
Health-Data Linkage and Symptom Surveillance
In general, the concept of linking commercial and health data
for early detection of cancer was perceived to be interesting and
people were conditionally willing to share their data. The key
conditions were having safeguards, transparency, and an option
to opt out or withdraw from the study. Safeguards included not
just data security, but also ensuring that the data would not be
used for purposes outside of the details provided in the initial
consent, as illustrated in the following quote:
If somebody checked the data on my phone, because
we had a cancer scare, it would be quite interesting
because I had gone on symptom checkers quite a lot,
so I think they’d have got quite a lot of data probably
from that, which might have been useful. So, I
wouldn’t disagree with that, it’s always this thing of
safeguards isn’t it? [Focus Group 4, Participant 27,
female, age 66]
The conditions also included transparency about the data
management and data sharing policies. Participants wanted clear
and concise information about the purpose and usage of their
data during the consent process. These were all related to
concerns about the misuse of the data by commercial gain.
I wouldn’t be averse to that for research purposes,
people being able to link things, as long as only
certain people had access to that and that it was
well-controlled and [with] data protection. [Focus
Group 2, Participant 10, female, age 34]
They do loads of these terms and conditions because
they know you’ll get bored before the end of it or
they’ll confuse you before you get to the end of it.
They should make that very clear at the box that it’s
only for their [researchers’] use. [Focus Group 3,
Participant 12, female, age 55]
Beliefs About Accuracy of the Data
While participants were intrigued by the potential to detect
cancer early through data linkages between commercial datasets
and health records, there was skepticism about the accuracy of
the data as well as the potential outcomes of misinterpretation.
This concern was toward the predictive utility of understanding
illness development, the presence of symptoms, and behavior
change, using data other than individual health records.
Do we understand yet a cure for cancer as a result
of some really good researchers and all our data? I
think that kind of story would be really convincing.
[Focus Group 3, Participant 17, male, age 53]
Relating to the predictive utility, participants questioned whether
the commercial data will be representative of the individuals’
actions and the symptoms they could be experiencing. The
reliability of data entered into the social media websites and
search engines were questioned by most focus groups. In
particular, concerns were raised about data entry on behalf of
someone else or for interest (eg, looking up someone else’s
symptoms on search engines). Participants also felt that people
are not open and honest about their actual behaviors on social
media websites and agreed that outcomes of social media data
analysis will have a “self-presentation bias.” In most focus
groups, participants proposed a preference and trust in objective
data (eg, tracker data and phone apps).
People start having the symptoms and they change
their eating habits, get more yoghurts or cut down on
the bread and things; could that not just be that our
taste buds change and we like bread for a while and
then go, “I’m fed up of bread.” And there’s actually
nothing wrong with us, it’s just... [Focus Group 3,
Participant 12, female, age 55]
Perceived Benefits
Participants agreed that if cancer symptom surveillance is found
to be effective, there may be a positive impact on research, an
increase in early diagnosis, and ultimately reduction in costs to
the National Health Service. A few mentioned that this could
reduce the pressure on emergency services and could support
general practitioners’ (GPs) decision-making processes if they
had a clear idea of the symptoms timeline. One participant,
however, perceived the impact to be more direct on his life and
expressed the potential impact that this research would have on
his partner and himself if her online data and consumer behavior
were researched before she was diagnosed with cancer.
So she started to feel tired, so she’s Googling
tiredness, but privately; then she’s got this pain in
her shoulders, so she started having physio on her
shoulders—this is from September to February. She’s
buying some painkillers or whatever and eventually
a lump appears under her arm and she went to the
doctor and it’s late-stage lung cancer; but she’s a
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very fit woman, so in those six months beforehand,
you look back now in time on reflection, it’s pretty
obvious that pain she was having was the tumor. So
that makes sense doesn’t it? It might give her a heads
up, “you’ve got a tumor here,” or “get checked out
for a tumor.”...So that early diagnosis makes complete
sense, however, is it for us as human beings to
discover stuff? I don’t know. I’m really interested to
hear. [Focus Group 3, Participant 17, male, age 53]
Considerations for Communication Strategies
Furthermore, the discussions included how people would like
to be informed about the outcomes if such analysis existed in
the future. Some participants preferred being directly informed
from a trusted source (eg, their GP). They felt direct letters with
a GP’s recommendation to themselves would prompt an action
toward early detection or prevention. Others preferred to be
informed by receiving a generalized public health message
where the outcome could be more informative rather than used
to highlight specific risk.
If someone found out something might be a pointer
towards a problem, I’d like it to go through the proper
channels and come from my GP rather than anyone
else really. [Focus Group 4, Participant 23, male, age
60]
I like to think if it was a very good advert, maybe some
compelling way of communicating with people, then
I would. I also feel like doing something in a
community that feels nicer to me than getting a
horrible email. [Focus Group 3, Participant 16,
female, age 26]
All participants felt that feedback from either of the options
would have to be communicated clearly to ensure that it does
not create any unwarranted anxiety among those who are not
actually having symptoms of cancer.
I’m just thinking that it might be too vague and that
you might give people an idea that they could have
cancer who are actually not at risk at all. I’m just
thinking that it might actually cause more anxiety in
people than it would do good. [Focus Group 2,
Participant 8, female, age 25]
Discussion
Principal Findings
This study demonstrates the potential to investigate patient
appraisal before someone starts having any symptoms and signs
related to cancer using real-time data collected by commercial
organizations. Our study showed that real-time data collected
by a commercial organization could offer insights to patients
before presentation at primary care. Furthermore, if this data
are used fairly and if the processes are transparent, the public
are willing to give consent to commercial- and health-data
linkages. It is also important to note that although it is feasible
to investigate commercial- and health-data linkages, there needs
to be further developments toward public trust in data accuracy
and communication strategies.
As stated, screening for ovarian cancer is not being
recommended [10] and the early detection of ovarian cancer
still remains a major public health problem. Although our study
had a limited sample size to detect differences between the cases
and the control group, we did observe purchases of pain and
indigestion medication in the ovarian cancer patients leading
up to diagnosis. Our findings are encouraging to pursue the
monitoring of self-care behaviors of ovarian cancer patients
with a large-scale, retrospective, case-control study. Although
the focus groups agreed that this data linkage was acceptable,
only 26% of the ovarian cancer patients approached for this
study consented to participate. One of the reasons for not
consenting may have been that they did not hold any requisite
loyalty cards, but this will need to be explored in future research.
We believe that past literature on self-care behaviors before
diagnosis and the emerging evidence supports this research
agenda. For instance, a recent study on the nature and the
frequency of abdominal symptoms suggest that patients with
persistent bloating and distention waited a minimum of two
months before presenting to primary care [27]. The identification
of self-care behaviors using commercial data could be an
effective approach to probe earlier engagement in primary care.
For ovarian cancer patients, specifically, this might mean an
increase in purchase of antacids to alleviate the feeling of
indigestion associated with bloating symptoms. It might also
mean a prolonged chronic use of pain medication to alleviate
stomach pain or back pain associated with ovarian cancer.
Furthermore, access to real-life data through high-street retailers,
trackers, and mobile phone apps will also open up other
opportunities for future research. For example, the link between
diet and cancer risk has been extensively studied in
epidemiological cohort studies, such as the European Prospective
Investigation into Cancer and Nutrition [28]. These studies have
traditionally used food frequency questionnaires to estimate
links between individuals’ diets and cancer incidence, which
have considerable recall bias and often only measure at very
few time points. Many other cancer types also have specific
symptoms that might be alleviated by over-the-counter
medications or monitored using loyalty card data. For example,
symptomatic esophageal cancer is often mistaken for indigestion
and gastroesophageal reflux [29], lung cancer is often mistaken
for persistent coughing [30], and pancreatic cancer is often
mistaken for abdominal pain and loss of appetite [31].
Furthermore, with a large enough cohort using an agnostic
approach with machine learning, one could discover novel
purchase behaviors associated with early cancer symptoms.
Strengths and Limitations
This proof-of-concept study was the first-ever research project
that aimed to understand self-care behaviors of cancer patients
prior to their diagnosis using commercial data. Therefore, we
have learned about the limitations of our proposed methodology
as we proceeded with the data collection. The limitations of our
study includes the small number of subjects that were available
for analysis of loyalty card data. Our data does not show
evidence of distinguishing between ovarian cancer patients and
control subjects given the small number of subjects. However,
it does show that it is feasible to analyze loyalty card data for
purchases such as pain and indigestion medication by patients
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prior to their diagnoses. Furthermore, it is also important to
clarify that identifying these purchases are not sufficient to
diagnose ovarian cancer, but should be sufficient to nudge the
patient to visit their GPs and discuss these symptoms as a
potential cancer-related symptom. Larger studies will be needed
to assess any statistical evidence to support our hypothesis that
purchase behavior may indicate cancer symptoms prior to
diagnosis and to assess the sensitivity and specificity of detecting
a cancer diagnosis. In retrospect, hair care products were not
an ideal comparator, particularly for the postdiagnosis period,
as there is a period during chemotherapy when hair care is not
particularly relevant to ovarian cancer patients, although it is
still relevant for the prediagnostic period. Other product
categories may be needed as control purchases for future studies.
Lastly, by using individual consent to analyze purchase
behaviors, we have also identified the most secure pathway to
analyze commercial data, which also fulfilled the criteria for
the commercial organization and the participants.
As the participants recruited for the focus groups were
self-selected, this may have introduced bias into the sample.
Although the focus groups were relatively diverse, with a broad
age range and a mixture of socioeconomic groups, the sample
was unbalanced for gender (70% female). This gender imbalance
is also observed with loyalty card usage, with the majority of
card holders from most high-street retailers being female, which
offers an insight about the target population for using loyalty
card data. The use of loyalty cards as a data source, in general,
has other limitations that need to be explored further. These
include the fact that people often buy for other family members,
not just themselves; they do not always use the card for every
purchase; they may often shop at other stores; or they may not
even hold any loyalty cards. Based on our data, approximately
half of the women held multiple loyalty cards from several
retailers and for these individuals the use of loyalty card data
will be of most value when combining data from several sources.
When conducting future studies, we will require the
collaboration of data analysts at multiple commercial
organizations to understand the variation in household data (eg,
the proportion of individuals who buy products on behalf of
others and a way to combine loyalty card data from multiple
retailers to understand an individuals’ purchasing behavior more
clearly). With the new General Data Protection Regulation by
the European Union and support by our focus group outcomes
on transparency and accountability, any other use of loyalty
card data and data linkage needs to be conducted with individual
consent and in a secure environment. Although this may be
perceived as a barrier to conducting large-scale projects or big
data analyses, we were able to fulfill focus group participants’
and supporting retailers’ criteria with our proposed methodology
using the CDRC secure laboratory.
Conclusions
In summary, we have shown that the potential use of
commercial- and health-data linkage for cancer symptom
surveillance was generally acceptable, with assurances for
transparency, security, and confidentiality. Our use of individual
purchase data, from loyalty card data from a high-street retailer,
was an appropriate source of this data to explore this novel
method for earlier diagnosis of ovarian cancer. There are a
number of exciting opportunities to use this data to investigate
novel methods of cancer surveillance and symptom recognition.
For example, unbiased machine learning-based approaches may
be used to discover novel purchase behaviors or interactions
between variables in these datasets to develop new hypotheses
that can be tested. Lastly, understanding when ovarian cancer
patients begin to self-medicate symptoms may provide more
direct empirical evidence for when symptoms occur prior to
diagnosis and improve our understanding of the natural
progression of this disease.
Availability of the Data and Material
The case study data for this research have been provided by the
CDRC, an ESRC Data Investment, under project ID CDRC
0018, ES/L011840/1; ES/L011891/1. Under CDRC license
agreement, the data included in the ovarian cancer case study
was limited to the purposes of this project and cannot be shared
with others. The anonymized focus group transcripts can be
made available from the corresponding author upon reasonable
request and will be assessed on a case-by-case basis. Users will
be required to complete a data-sharing agreement.
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